Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results